37 results
Thumbnail

D2.394 - Mycoplasma-Induced Drug Hypersensitivity: Rare Complication or Coincidence?

Thumbnail

D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients

Thumbnail

D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity

Thumbnail

D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children

Thumbnail

D2.403 - When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem

Thumbnail

D2.405 - UnDRESSing AGEP and Revealing Erythema Multiforme

Thumbnail

D2.406 - Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges

Thumbnail

D2.393 - Aspirin hypersensitivity and desensitization-Sense and sensibility

Thumbnail

D2.396 - Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol

Thumbnail

D2.397 - Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case

Thumbnail

D2.398 - Ibuprofen Challenge or Desensitisation in Myo-Pericardial Disease: A Case Series

Thumbnail

D2.400 - Vitamin Hypersensitivity in the Era of Intravenous ‘Cocktails’: Diagnostic Pitfalls and Clinical Consequences

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to